Trials / Recruiting
RecruitingNCT06551337
Vitamin D Replacement in Bronchiectasis
Prospective Clinical Study on Vitamin D Replacement in Bronchiectasis - A Pilot Study
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Queen Mary Hospital, Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to address the limitations in previous related studies on vitamin D replacement and bronchiectasis exacerbation occurrence through a self-controlled pilot study. The investigators aim to investigate whether vitamin D replacement in bronchiectasis patients with vitamin D deficiency can reduce hospitalized bronchiectasis exacerbation occurrence. Patients who participated in the prior study entitled "Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation" (UW 22-317) will be invited for participation during regular clinic follow-up and management in Queen Mary Hospital. If participants are willing to join the further research, participants will be recruited in this self-controlled study. There are some differences from usual management to non-CF bronchiectasis subjects. The study subjects would be checked for their blood 25-hydroxyvitamin-D level during the study period. The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU (if needed). The investigators aim to correct their Vitamin D deficiency completely, aiming at blood 25-hydroxyvitamin-D level \>=50, i.e. treat to target. The dose depends on the level of Vitamin D after replacement. If blood 25-hydroxyvitamin-D level is 50 or above, then 1000 IU is suffice. If blood 25-hydroxyvitamin-D level is still below 50, the investigators will increase to 2000 IU.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vitamin D3 | The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU. |
Timeline
- Start date
- 2024-04-17
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2024-08-13
- Last updated
- 2024-08-13
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT06551337. Inclusion in this directory is not an endorsement.